Woodward patents expiration
1. Aciphex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5045552 | WOODWARD | Pyridine derivatives having anti-ulcerative activity |
May, 2013
(10 years ago) | |
|
US5045552 (Pediatric) | WOODWARD | Pyridine derivatives having anti-ulcerative activity |
Nov, 2013
(10 years ago) | |
Drugs and Companies using RABEPRAZOLE SODIUM ingredient
Market Authorisation Date: 29 May, 2002
Treatment: Treatment of peptic ulcers
Dosage: TABLET, DELAYED RELEASE;ORAL
ACIPHEX family patents
2. Avandia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5741803 | WOODWARD | Substituted thiazolidinedionle derivatives |
Apr, 2015
(9 years ago) | |
| US7358366 | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Apr, 2020
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5741803 (Pediatric) | WOODWARD | Substituted thiazolidinedionle derivatives |
Oct, 2015
(8 years ago) | |
| US6288095 | WOODWARD | Compounds |
Feb, 2017
(7 years ago) | |
|
US6288095 (Pediatric) | WOODWARD | Compounds |
Aug, 2017
(6 years ago) | |
|
US7358366 (Pediatric) | WOODWARD | Thiazolidinedione derivative and its use as antidiabetic |
Oct, 2020
(3 years ago) | |
Drugs and Companies using ROSIGLITAZONE MALEATE ingredient
Market Authorisation Date: 25 May, 1999
Treatment: Method of treatment of type ii diabetes; Use of avandia as monotherapy, in combination with metformin, and in combination with sulfonylureas to improve glycemic control in patients with type 2 diabete...
Dosage: TABLET;ORAL
AVANDIA family patents
3. Avodart patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5998427 | WOODWARD | Androstenones |
Sep, 2013
(10 years ago) | |
| US5565467 | WOODWARD | Androstenone derivative |
Nov, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5846976 | WOODWARD | Androstenone derivative |
Sep, 2013
(10 years ago) | |
Drugs and Companies using DUTASTERIDE ingredient
Market Authorisation Date: 20 November, 2001
Treatment: Method of treating androgen responsive/mediated condition in mammal by admin a safe, effective amount of dutasteride or pharmaceutically acceptable derivative thereof..conditions include benign prosta...
Dosage: CAPSULE;ORAL
AVODART family patents
4. Coreg patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40000 | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Jun, 2015
(8 years ago) | |
|
USRE40000 (Pediatric) | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Dec, 2015
(8 years ago) | |
Drugs and Companies using CARVEDILOL ingredient
Market Authorisation Date: 29 May, 1997
Treatment: Decreasing mortality caused by congestive heart failure
Dosage: TABLET;ORAL
COREG family patents
5. Coreg Cr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7268156 | WOODWARD | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Jun, 2023
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40000 | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Jun, 2015
(8 years ago) | |
| US6022562 | WOODWARD | Medicinal and/or nutritional microcapsules for oral administration |
Oct, 2015
(8 years ago) | |
|
USRE40000 (Pediatric) | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Dec, 2015
(8 years ago) | |
|
US6022562 (Pediatric) | WOODWARD | Medicinal and/or nutritional microcapsules for oral administration |
Apr, 2016
(8 years ago) | |
|
US7268156 (Pediatric) | WOODWARD | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Dec, 2023
(3 months ago) | |
| US8101209 | WOODWARD | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Sep, 2025
(1 year, 4 months from now) | |
|
US8101209 (Pediatric) | WOODWARD | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Mar, 2026
(1 year, 10 months from now) | |
Drugs and Companies using CARVEDILOL PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2006
Treatment: Decreasing mortality caused by congestive heart failure; Treatment of hypertension
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
COREG CR family patents
6. Jalyn patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5998427 | WOODWARD | Androstenones |
Sep, 2013
(10 years ago) | |
| US5565467 | WOODWARD | Androstenone derivative |
Nov, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5846976 | WOODWARD | Androstenone derivative |
Sep, 2013
(10 years ago) | |
Drugs and Companies using DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 June, 2010
Treatment: Method of treating androgen responsive or medicated condition in a mammal by administering a safe & effective amount of dutasteride or a pharmaceutically acceptable solvate thereof.. conditions includ...
Dosage: CAPSULE;ORAL
JALYN family patents
7. Lovaza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5502077 | WOODWARD | Fatty acid composition |
Mar, 2013
(11 years ago) | |
| US5656667 | WOODWARD | Fatty acid composition |
Apr, 2017
(7 years ago) | |
| US7732488 | WOODWARD | Pharmaceutical composition comprising low concentrations of environmental pollutants |
Jan, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-87) | Sep 16, 2012 |
Drugs and Companies using OMEGA-3-ACID ETHYL ESTERS ingredient
Market Authorisation Date: 10 November, 2004
Treatment: Use in lipid management
Dosage: CAPSULE;ORAL
LOVAZA family patents
8. Lunesta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6444673 | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Feb, 2014
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6319926 (Pediatric) | WOODWARD | Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Jul, 2012
(11 years ago) | |
|
US7381724 (Pediatric) | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same |
Jul, 2012
(11 years ago) | |
| US6864257 | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug, 2012
(11 years ago) | |
|
US6864257 (Pediatric) | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Mar, 2013
(11 years ago) | |
|
US6444673 (Pediatric) | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug, 2014
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Apr 10, 2016 |
| M(M-61) | Oct 10, 2015 |
Drugs and Companies using ESZOPICLONE ingredient
Market Authorisation Date: 15 December, 2004
Treatment: Method of inducing a hypnotic or sedative effect in a human by administering eszopiclone
Dosage: TABLET;ORAL
LUNESTA family patents